Standard

Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. / Meeter, Lieke H.H.; Steketee, Rebecca M.E.; Salkovic, Dina; Vos, Maartje E.; Grossman, Murray; McMillan, Corey T.; Niessen, Wiro J.; Papma, Janne M.; De Jong, Frank Jan; More Authors.

In: Journal of Neurology, Neurosurgery and Psychiatry, 2019.

Research output: Contribution to journalArticleScientificpeer-review

Harvard

Meeter, LHH, Steketee, RME, Salkovic, D, Vos, ME, Grossman, M, McMillan, CT, Niessen, WJ, Papma, JM, De Jong, FJ & More Authors 2019, 'Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia' Journal of Neurology, Neurosurgery and Psychiatry. https://doi.org/10.1136/jnnp-2018-319784

APA

Meeter, L. H. H., Steketee, R. M. E., Salkovic, D., Vos, M. E., Grossman, M., McMillan, C. T., ... More Authors (2019). Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry. https://doi.org/10.1136/jnnp-2018-319784

Vancouver

Meeter LHH, Steketee RME, Salkovic D, Vos ME, Grossman M, McMillan CT et al. Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry. 2019. https://doi.org/10.1136/jnnp-2018-319784

Author

Meeter, Lieke H.H. ; Steketee, Rebecca M.E. ; Salkovic, Dina ; Vos, Maartje E. ; Grossman, Murray ; McMillan, Corey T. ; Niessen, Wiro J. ; Papma, Janne M. ; De Jong, Frank Jan ; More Authors. / Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. In: Journal of Neurology, Neurosurgery and Psychiatry. 2019.

BibTeX

@article{19a08116c7294ef69a1d34b55aabdfc9,
title = "Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia",
abstract = "Background: Semantic dementia (SD) is a neurodegenerative disorder characterised by progressive language problems falling within the clinicopathological spectrum of frontotemporal lobar degeneration (FTLD). The development of disease-modifying agents may be facilitated by the relative clinical and pathological homogeneity of SD, but we need robust monitoring biomarkers to measure their efficacy. In different FTLD subtypes, neurofilament light chain (NfL) is a promising marker, therefore we investigated the utility of cerebrospinal fluid (CSF) NfL in SD. Methods: This large retrospective multicentre study compared cross-sectional CSF NfL levels of 162 patients with SD with 65 controls. CSF NfL levels of patients were correlated with clinical parameters (including survival), neuropsychological test scores and regional grey matter atrophy (including longitudinal data in a subset). Results: CSF NfL levels were significantly higher in patients with SD (median: 2326 pg/mL, IQR: 1628-3593) than in controls (577 (446-766), p<0.001). Higher CSF NfL levels were moderately associated with naming impairment as measured by the Boston Naming Test (rs=-0.32, p=0.002) and with smaller grey matter volume of the parahippocampal gyri (rs=-0.31, p=0.004). However, cross-sectional CSF NfL levels were not associated with progression of grey matter atrophy and did not predict survival. Conclusion: CSF NfL is a promising biomarker in the diagnostic process of SD, although it has limited cross-sectional monitoring or prognostic abilities.",
author = "Meeter, {Lieke H.H.} and Steketee, {Rebecca M.E.} and Dina Salkovic and Vos, {Maartje E.} and Murray Grossman and McMillan, {Corey T.} and Niessen, {Wiro J.} and Papma, {Janne M.} and {De Jong}, {Frank Jan} and {More Authors}",
year = "2019",
doi = "10.1136/jnnp-2018-319784",
language = "English",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",

}

RIS

TY - JOUR

T1 - Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia

AU - Meeter, Lieke H.H.

AU - Steketee, Rebecca M.E.

AU - Salkovic, Dina

AU - Vos, Maartje E.

AU - Grossman, Murray

AU - McMillan, Corey T.

AU - Niessen, Wiro J.

AU - Papma, Janne M.

AU - De Jong, Frank Jan

AU - More Authors, null

PY - 2019

Y1 - 2019

N2 - Background: Semantic dementia (SD) is a neurodegenerative disorder characterised by progressive language problems falling within the clinicopathological spectrum of frontotemporal lobar degeneration (FTLD). The development of disease-modifying agents may be facilitated by the relative clinical and pathological homogeneity of SD, but we need robust monitoring biomarkers to measure their efficacy. In different FTLD subtypes, neurofilament light chain (NfL) is a promising marker, therefore we investigated the utility of cerebrospinal fluid (CSF) NfL in SD. Methods: This large retrospective multicentre study compared cross-sectional CSF NfL levels of 162 patients with SD with 65 controls. CSF NfL levels of patients were correlated with clinical parameters (including survival), neuropsychological test scores and regional grey matter atrophy (including longitudinal data in a subset). Results: CSF NfL levels were significantly higher in patients with SD (median: 2326 pg/mL, IQR: 1628-3593) than in controls (577 (446-766), p<0.001). Higher CSF NfL levels were moderately associated with naming impairment as measured by the Boston Naming Test (rs=-0.32, p=0.002) and with smaller grey matter volume of the parahippocampal gyri (rs=-0.31, p=0.004). However, cross-sectional CSF NfL levels were not associated with progression of grey matter atrophy and did not predict survival. Conclusion: CSF NfL is a promising biomarker in the diagnostic process of SD, although it has limited cross-sectional monitoring or prognostic abilities.

AB - Background: Semantic dementia (SD) is a neurodegenerative disorder characterised by progressive language problems falling within the clinicopathological spectrum of frontotemporal lobar degeneration (FTLD). The development of disease-modifying agents may be facilitated by the relative clinical and pathological homogeneity of SD, but we need robust monitoring biomarkers to measure their efficacy. In different FTLD subtypes, neurofilament light chain (NfL) is a promising marker, therefore we investigated the utility of cerebrospinal fluid (CSF) NfL in SD. Methods: This large retrospective multicentre study compared cross-sectional CSF NfL levels of 162 patients with SD with 65 controls. CSF NfL levels of patients were correlated with clinical parameters (including survival), neuropsychological test scores and regional grey matter atrophy (including longitudinal data in a subset). Results: CSF NfL levels were significantly higher in patients with SD (median: 2326 pg/mL, IQR: 1628-3593) than in controls (577 (446-766), p<0.001). Higher CSF NfL levels were moderately associated with naming impairment as measured by the Boston Naming Test (rs=-0.32, p=0.002) and with smaller grey matter volume of the parahippocampal gyri (rs=-0.31, p=0.004). However, cross-sectional CSF NfL levels were not associated with progression of grey matter atrophy and did not predict survival. Conclusion: CSF NfL is a promising biomarker in the diagnostic process of SD, although it has limited cross-sectional monitoring or prognostic abilities.

UR - http://www.scopus.com/inward/record.url?scp=85066140649&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2018-319784

DO - 10.1136/jnnp-2018-319784

M3 - Article

JO - Journal of Neurology, Neurosurgery and Psychiatry

T2 - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

ER -

ID: 54238947